United Therapeutics Statistics
Want to see UTHR full AI Analyst Report?
United Therapeutics (UTHR) Stock Statistics & Valuation Metrics
Total Valuation
United Therapeutics has a market cap or net worth of $23.94B. The enterprise value is $22.48B.
- Market Cap
- $23.94B
- Enterprise Value
- $22.48B
Share Statistics
United Therapeutics has 42,588,726 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 42,588,726
- Owned by Insiders
- 1.96%
- Owned by Institutions
- 59.45%
Financial Efficiency
United Therapeutics’s return on equity (ROE) is 0.19 and return on invested capital (ROIC) is 16.13%.
- Return on Equity (ROE)
- 0.19
- Return on Assets (ROA)
- 0.17
- Return on Invested Capital (ROIC)
- 16.13%
- Return on Capital Employed (ROCE)
- 0.21
- Revenue Per Employee
- 2.27M
- Profits Per Employee
- 953.36K
- Employee Count
- 1,400
- Asset Turnover
- 0.40
- Inventory Turnover
- 2.10
Valuation Ratios
The current PE Ratio of United Therapeutics is 20.39. United Therapeutics’s PEG ratio is 116.29.
- PE Ratio
- 20.39
- PS Ratio
- 7.84
- PB Ratio
- 3.96
- Price to FCF
- 28.81
- Price to Operating Cash Flow
- 17.40
- PEG Ratio
- 116.29
Income Statement
In the last 12 months, United Therapeutics had revenue of 3.18B and earned 1.33B in profits. Earnings per share was 30.13.
- Revenue
- 3.18B
- Gross Profit
- 2.80B
- Operating Income
- 1.52B
- Pretax Income
- 1.71B
- Net Income
- 1.33B
- EBITDA
- 1.82B
- Earnings Per Share (EPS)
- 30.13
Cash Flow
In the last 12 months, operating cash flow was 1.43B and capital expenditures -562.40M, giving a free cash flow of 867.20M billion.
- Operating Cash Flow
- 1.43B
- Free Cash Flow
- 867.20M
- Free Cash Flow per Share
- 20.31
Dividends & Yields
United Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 3.47%
- Earnings Yield
- 4.95%
Stock Price Statistics
- Beta
- 0.55
- 52-Week Price Change
- 23.79%
- 50-Day Moving Average
- 533.44
- 200-Day Moving Average
- 535.45
- Relative Strength Index (RSI)
- 48.93
- Average Volume (3m)
- 696.91K
Important Dates
United Therapeutics upcoming earnings date is Feb 24, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 04, 2026
- Next Earnings Date
- Feb 24, 2027
- Ex-Dividend Date
- ―
Financial Position
United Therapeutics as a current ratio of 6.60, with Debt / Equity ratio of 0.53%
- Current Ratio
- 6.60
- Quick Ratio
- 6.28
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -0.84
- Interest Coverage Ratio
- 77.81
Taxes
In the past 12 months, United Therapeutics has paid 379.20M in taxes.
- Income Tax
- 379.20M
- Effective Tax Rate
- 0.22
Enterprise Valuation
United Therapeutics EV to EBITDA ratio is 15.04, with an EV/FCF ratio of 27.44.
- EV to Sales
- 7.46
- EV to EBITDA
- 15.04
- EV to Free Cash Flow
- 27.44
- EV to Operating Cash Flow
- 16.64
Balance Sheet
United Therapeutics has $2.07B in cash and marketable securities with $0.00 in debt, giving a net cash position of $2.07B billion.
- Cash & Marketable Securities
- $2.07B
- Total Debt
- $0.00
- Net Cash
- $2.07B
- Net Cash Per Share
- $48.56
- Tangible Book Value Per Share
- $144.30
Margins
Gross margin is 86.34%, with operating margin of 41.47%, and net profit margin of 38.61%.
- Gross Margin
- 86.34%
- Operating Margin
- 41.47%
- Pretax Margin
- 47.30%
- Net Profit Margin
- 38.61%
- EBITDA Margin
- 49.63%
- EBIT Margin
- 46.62%
Analyst Forecast
The average price target for United Therapeutics is $682.71, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $682.71
- Price Target Upside
- 21.48% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 14
- Revenue Growth Forecast
- 1.89%
- EPS Growth Forecast
- 0.33%
Scores
- Smart Score
- 9
- AI Score
- 85
